AI Article Synopsis

  • Natural resistance of HIV-1 to therapies presents challenges, particularly for the reverse transcriptase (RT), a key target in drug development.
  • Researchers found that a specific ssDNA aptamer, RT1t49, effectively inhibits RT from various HIV strains with a strong binding affinity.
  • The study demonstrated that RT1t49 works alongside existing treatments, enhancing their effectiveness against HIV and SIV, and suggests that resistance to this aptamer is rare.

Article Abstract

Natural and selected resistance of HIV-1 to current anti-HIV drugs continues to pose serious problems to the development of HIV-1 antivirals. The viral reverse transcriptase (RT) is a proven therapeutic target. Single-stranded RNA and DNA (ssRNA and ssDNA) aptamers have been selected that specifically and potently inhibit RT function. In particular, the ssDNA aptamer RT1t49 was previously selected to recognize the RT from a subtype B strain of HIV-1 and binds with a reported K(d) of 4 nM. In the present work, we show that RT1t49 inhibits recombinant RT cloned from diverse branches of the primate lentiviral family. Aptamer concentrations required for half-maximal inhibition of all HIV-1, HIV-2, and SIV(CPZ) RTs assayed were in the low-to mid-nanomolar range for both polymerase and RNase H activities. Using pre-steady-state and order-of-addition kinetic analyses, we also established that this ssDNA aptamer competes with primer-template for access to RT, and that addition of a nucleoside analog RT inhibitor (NRTI) to the in vitro reaction enhanced the overall effectiveness of both drugs, while nonnucleoside analog RT inhibitors (NNRTIs) exhibited simple additivity. This is the first demonstration of universal inhibition of HIV and SIV(cpz) RTs by a nucleic acid aptamer and supports previous reports suggesting that resistance to RT1t49 may be exceptionally infrequent.

Download full-text PDF

Source
http://dx.doi.org/10.1089/aid.2006.0262DOI Listing

Publication Analysis

Top Keywords

sivcpz rts
12
aptamer rt1t49
8
rt1t49 inhibits
8
polymerase rnase
8
hiv type
8
ssdna aptamer
8
aptamer
5
single-stranded dna
4
dna aptamer
4
rt1t49
4

Similar Publications

A detailed understanding of how aptamers recognize biological binding partners is of considerable importance in the development of oligonucleotide therapeutics. For antiviral nucleic acid aptamers, current models predict a correlation between broad-spectrum inhibition of viral proteins and suppression of emerging viral resistance, but there is little understanding of how aptamer structures contribute to recognition specificity. We previously established that two independent single-stranded DNA aptamers, R1T and RT1t49(-5), are potent inhibitors of reverse transcriptases (RTs) from diverse branches of the primate lentiviral family, including HIV-1, HIV-2 and SIV(cpz).

View Article and Find Full Text PDF
Article Synopsis
  • Natural resistance of HIV-1 to therapies presents challenges, particularly for the reverse transcriptase (RT), a key target in drug development.
  • Researchers found that a specific ssDNA aptamer, RT1t49, effectively inhibits RT from various HIV strains with a strong binding affinity.
  • The study demonstrated that RT1t49 works alongside existing treatments, enhancing their effectiveness against HIV and SIV, and suggests that resistance to this aptamer is rare.
View Article and Find Full Text PDF

Reverse transcriptase (RT) remains a primary target in therapies directed at human immunodeficiency virus type 1 (HIV-1). RNA aptamers that bind RT from HIV-1 subtype B have been shown to protect human cells from infection and to reduce viral infectivity, but little is known about the sensitivity of the inhibition to amino sequence variations of the RT target. Therefore, we assembled a panel of 10 recombinant RTs from phylogenetically diverse lentiviral isolates (including strains of HIV-1, simian immunodeficiency virus SIVcpz, and HIV-2).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!